guest ::
| Home > Publications database > Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences > print |
| Home > Publications database > Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences > print |
| 001 | 7089 | ||
| 005 | 20210129210433.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:20870148 |
| 024 | 7 | _ | |2 DOI |a 10.1016/j.nucmedbio.2010.04.185 |
| 024 | 7 | _ | |2 WOS |a WOS:000282803500001 |
| 024 | 7 | _ | |2 ISSN |a 1872-9414 |
| 024 | 7 | _ | |a altmetric:7408224 |2 altmetric |
| 037 | _ | _ | |a PreJuSER-7089 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 084 | _ | _ | |2 WoS |a Radiology, Nuclear Medicine & Medical Imaging |
| 100 | 1 | _ | |0 P:(DE-Juel1)131816 |a Coenen, H. H. |b 0 |u FZJ |
| 245 | _ | _ | |a Fluorine-18 radiopharmaceuticals (beyond [18F]FDG) for use in oncology and neurosciences |
| 260 | _ | _ | |a Amsterdam [u.a.] |b Elsevier |c 2010 |
| 295 | 1 | 0 | |a Report of an IAEA Consultants Group Meeting |
| 300 | _ | _ | |a 727 - 740 |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |2 DRIVER |a article |
| 440 | _ | 0 | |0 4644 |a Nuclear Medicine and Biology |v 37 |x 0883-2897 |y 7 |
| 500 | _ | _ | |a The Consultants acknowledge the IAEA for its interest and activities in this important field. The authors from the IAEA (MRAP and JJZ) thank Dr. M. Haji-Saeid, Head, Industrial Applications and Chemistry Section, Dr. M. Dondi, Head, Nuclear Medicine Section, and Dr N. Ramamoorthy, Director-NAPC, International Atomic Energy Agency for their support and encouragement. |
| 520 | _ | _ | |a Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences. |
| 536 | _ | _ | |0 G:(DE-Juel1)FUEK409 |2 G:(DE-HGF) |x 0 |c FUEK409 |a Funktion und Dysfunktion des Nervensystems (FUEK409) |
| 536 | _ | _ | |0 G:(DE-HGF)POF2-89572 |a 89572 - (Dys-)function and Plasticity (POF2-89572) |c POF2-89572 |f POF II T |x 1 |
| 588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
| 650 | _ | 2 | |2 MeSH |a Animals |
| 650 | _ | 2 | |2 MeSH |a Fluorodeoxyglucose F18: diagnostic use |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Neoplasms: radionuclide imaging |
| 650 | _ | 2 | |2 MeSH |a Nervous System Diseases: radionuclide imaging |
| 650 | _ | 2 | |2 MeSH |a Radiopharmaceuticals: diagnostic use |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Radiopharmaceuticals |
| 650 | _ | 7 | |0 63503-12-8 |2 NLM Chemicals |a Fluorodeoxyglucose F18 |
| 650 | _ | 7 | |2 WoSType |a J |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Elsinga, P.H. |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Iwata, R. |b 2 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kilbourn, M.R. |b 3 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Pillai, M.R.A. |b 4 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Rajan, M.G.R. |b 5 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Wagner, H.N. |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Zaknun, J. |b 7 |
| 773 | _ | _ | |0 PERI:(DE-600)1498538-x |a 10.1016/j.nucmedbio.2010.04.185 |g Vol. 37, p. 727 - 740 |p 727 - 740 |q 37<727 - 740 |t Nuclear medicine and biology |v 37 |x 1872-9614 |y 2010 |
| 856 | 7 | _ | |u http://dx.doi.org/10.1016/j.nucmedbio.2010.04.185 |
| 909 | C | O | |o oai:juser.fz-juelich.de:7089 |p VDB |
| 913 | 2 | _ | |0 G:(DE-HGF)POF3-572 |1 G:(DE-HGF)POF3-570 |2 G:(DE-HGF)POF3-500 |a DE-HGF |b Key Technologies |l Decoding the Human Brain |v (Dys-)function and Plasticity |x 0 |
| 913 | 1 | _ | |0 G:(DE-HGF)POF2-89572 |a DE-HGF |v (Dys-)function and Plasticity |x 1 |4 G:(DE-HGF)POF |1 G:(DE-HGF)POF3-890 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |b Programmungebundene Forschung |l ohne Programm |
| 914 | 1 | _ | |y 2010 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |g INM |k INM-5 |l Nuklearchemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-82)080010_20140620 |g JARA |k JARA-BRAIN |l Jülich-Aachen Research Alliance - Translational Brain Medicine |x 1 |
| 970 | _ | _ | |a VDB:(DE-Juel1)115607 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a I:(DE-82)080010_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)VDB1046 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|